TYK2 and psoriasis: The systematic review partially confirmed the safety of JAK inhibitors in IMIDs.<h4>Conclusion</h4>This study supports TYK2 inhibition as a targeted therapy for psoriasis and provides hypothesis-generating genetic evidence for additional target-disease and target-safety associations that warrant further validation.